States aim to join Wyeth whistleblower suits

Seventeen states have asked to join two whistleblower lawsuits that allege Wyeth kept mum about discounts it had offered on its Protonix drugs, depriving Medicaid of the same prices. If the court

SC nominee backed Merck shareholder suit

Want a pharma connection to President Obama's new Supreme Court nominee Elana Kagan? As U.S. Solicitor General, Kagan backed the shareholders who were suing Merck (NYSE: MRK) over claims that the

Studies ID drawbacks of PPIs, Parkinson's meds, birth control

Data, data and more data are questioning the side effects of some key drugs. As published in this week's medical journals, new studies have tagged proton pump inhibitors, Parkinsons' drugs, and birth

Sources: First 700 Avandia suits settled for $60M

If the first round of Avandia settlements sets the trend, GlaxoSmithKline (NYSE: GSK) could suffer a lot less from the thousands of lawsuits filed over the diabetes drug. Sources tell Bloomberg the

GSK beefs up in S. Korea with Dong-A alliance

Proving once again that emerging markets are where it's at, GlaxoSmithKline (NYSE: GSK) has inked a strategic alliance in South Korea. The British company will buy a 9.9 percent stake in Dong-A

Pfizer to sell NY building, cut up to 1,400 jobs

Pfizer (NYSE: PFE) slapped a For Sale sign on a Manhattan high-rise yesterday as it prepares to lay off or move up to 1,400 employees who work in the city, the New York Times reports. That's about

Novartis CEO goes on a 'decluttering' drive

New Novartis (NYSE:NVS) chief Joe Jiminez (photo) is talking execution again. In an interview with the Financial Times, Jiminez described some of his initiatives--and they're all about the E word.

GSK chief says two buyout deals in works

GlaxoSmithKline (NYSE: GSK) CEO Andrew Witty (photo) plans to announce two "small" acquisitions soon, after walking away from five potential purchases or partnerships since October. Report

Teva: Frugal, feisty and full of growth plans

Does Teva (NASDAQ: TEVA) "just do it better"? You be the judge. In a profile, the New York Times juxtaposes the company's astonishing growth over the last 10 years--growth in sales to $14 billion

Weldon is disappointed as J&J recall spawns another probe

The fallout continues from Johnson & Johnson's (NYSE: JNJ) big recall of over-the-counter children's meds. Another U.S. rep is demanding information, this time from the FDA, questioning whether

FDA panel: Rotavirus vaccines worth any PCV risk

It's a rotavirus reprieve. An FDA panel backed continued use of vaccines against the diarrhea-causing germ from both Merck (NYSE: MRK) and GlaxoSmithKline (NYSE: GSK), in spite of trace contamination

Jury slams Teva, Baxter with $500M in damages

A district court jury in Nevada has ordered Teva Pharmaceutical Industries (NASDAQ: TEVA) and Baxter International (NYSE: BAX) to pay a combined $500 million--the largest such award in state

PE fund commits $1.1B to inVentiv buyout

The stock market might be iffy about healthcare reform's short-term effects on drugmakers, but a private equity firm has just placed a $1.1 billion bet that a pharmaceutical services firm will thrive

Genzyme to jettison three units as it bunkers down

Under assault by Carl Icahn and facing stiff regulatory oversight following some embarrassing manufacturing blunders, Genzyme is getting back to basics. In a series of strategic moves, the biotech

Canadian provinces mull joint drug-price cuts

Every Canadian province is watching Ontario, which last month overhauled its drug-pricing scheme to combat the rising cost of generic drugs. The province aims to stop "professional allowances" paid

Lilly slices 200 sales and marketing jobs in biomedicine

The ax will fall today on some 200 sales and marketing support jobs at Eli Lilly, the Indianapolis Star reports. The cuts will come in Lilly's U.S. biomedicine group, and more than half of the job

Pig-virus DNA found in Merck's rotavirus vax

Remember that pig-virus DNA that turned up in GlaxoSmithKline's vaccine against the diarrhea-causing rotavirus? Well, DNA from the same pig germ has surfaced in Merck's rotavirus preventive. And both

Sales reps face rising tide of inaccessible docs

Pharma sales reps are finding an increasingly hostile world out there. The fraction of doctors willing to meet reps regularly has dropped significantly. And the group unwilling to see reps at all has

Novartis in thicket of H1N1 vaccine cancellations

Never again, Novartis says. Never again will it structure its pandemic vaccine contracts the way it did last year. That's because about half of the 15 governments that ordered H1N1 flu vaccine from

Sanofi cuts 70 Canadian jobs in streamlining

Sanofi-Aventis Canada is streamlining its Canadian operations and cutting up to 70 jobs across the country as it loses patent protection on some of its drugs. Report